Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Richter's syndrome
- Focus Adverse reactions; Therapeutic Use
- 10 Jan 2025 Planned End Date changed from 1 May 2026 to 1 Nov 2026.
- 10 Jan 2025 Planned primary completion date changed from 1 Nov 2024 to 1 May 2025.
- 23 Jul 2024 Planned primary completion date changed from 1 May 2024 to 1 Nov 2024.